Adriano Chiò is a neurologist currently working in Torino, Italy. He is Professor of Neurology and Director of the 1st Neurology Unit at the University of Torino and the Città della Salute e della Scienza Hospital, Torino, Italy. He obtained his medical degree from the University of Turin. He completed his residency in Neurology in Turin and in Clinical Neurophysiology in Pavia. He is a founding member Chairman of the Italian Neuroepidemiology Association. He is a member of the board and currently Treasurer of the European Network for the Cure of ALS (ENCALS). He leads the Italian ALS Genetic (ITALSGEN) Consortium. He is director of the ALS Expert Center in Torino, that aims for optimal diagnostic work-up, care and treatment for patients with ALS/FTD and other motor neuron diseases in Piedmont. Adriano Chiò, whose main areas of research are epidemiology, cognition, neuroimaging, and genetics of ALS, is best known for his research on risk of ALS in soccer players, the phenotypic heterogeneity of ALS and has contributed to the discovering of several ALS genes, including C9ORF72, VCP, MATR3 and KIF5A. He has published over 350 papers in peer-reviewed journals. He was awarded the 2015 Sheila Essay Award, presented by the American Academy of Neurology and ALS Association (USA).
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.